These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 28255338)

  • 1. Apremilast in the treatment of psoriatic arthritis: a perspective review.
    Reed M; Crosbie D
    Ther Adv Musculoskelet Dis; 2017 Feb; 9(2):45-53. PubMed ID: 28255338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug safety evaluation of apremilast for treating psoriatic arthritis.
    Busa S; Kavanaugh A
    Expert Opin Drug Saf; 2015 Jun; 14(6):979-85. PubMed ID: 25827658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis.
    Mease PJ
    Rheumatol Ther; 2014 Dec; 1(1):1-20. PubMed ID: 27747762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Keating GM
    Drugs; 2017 Mar; 77(4):459-472. PubMed ID: 28213862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.
    Cutolo M; Myerson GE; Fleischmann RM; Lioté F; Díaz-González F; Van den Bosch F; Marzo-Ortega H; Feist E; Shah K; Hu C; Stevens RM; Poder A
    J Rheumatol; 2016 Sep; 43(9):1724-34. PubMed ID: 27422893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies.
    Elyoussfi S; Thomas BJ; Ciurtin C
    Rheumatol Int; 2016 May; 36(5):603-12. PubMed ID: 26892034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis.
    Abdulrahim H; Thistleton S; Adebajo AO; Shaw T; Edwards C; Wells A
    Expert Opin Pharmacother; 2015 May; 16(7):1099-108. PubMed ID: 25864487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Deeks ED
    Drugs; 2015 Aug; 75(12):1393-403. PubMed ID: 26220911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis.
    Kavanaugh A; Gladman DD; Edwards CJ; Schett G; Guerette B; Delev N; Teng L; Paris M; Mease PJ
    Arthritis Res Ther; 2019 May; 21(1):118. PubMed ID: 31077258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
    Edwards CJ; Blanco FJ; Crowley J; Birbara CA; Jaworski J; Aelion J; Stevens RM; Vessey A; Zhan X; Bird P
    Ann Rheum Dis; 2016 Jun; 75(6):1065-73. PubMed ID: 26792812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis.
    Metyas S; Tomassian C; Messiah R; Gettas T; Chen C; Quismorio A
    Curr Rheumatol Rev; 2019; 15(3):234-237. PubMed ID: 30499418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on the treatment of psoriasis and psoriatic arthritis - role of apremilast.
    Forchhammer S; Ghoreschi K
    Psoriasis (Auckl); 2015; 5():117-124. PubMed ID: 29387588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety evaluation of apremilast for the treatment of psoriasis.
    Dattola A; Del Duca E; Saraceno R; Gramiccia T; Bianchi L
    Expert Opin Drug Saf; 2017 Mar; 16(3):381-385. PubMed ID: 28132578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apremilast in psoriatic arthritis.
    Schett G
    Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S98-100. PubMed ID: 26472278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apremilast in the Treatment of Plaque Psoriasis: Differential Use in Psoriasis.
    Gao JC; Wu AG; Contento MN; Maher JM; Cline A
    Clin Cosmet Investig Dermatol; 2022; 15():395-402. PubMed ID: 35300435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Metabolic Effect on Serum Lipids of Apremilast in Psoriatic Arthritis: A Case Report.
    Gualtierotti R; De Lucia O
    J Clin Med; 2019 Mar; 8(3):. PubMed ID: 30909370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
    Kawalec P; Holko P; Moćko P; Pilc A
    Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-naïve patients with psoriatic arthritis.
    Betts KA; Griffith J; Friedman A; Zhou ZY; Signorovitch JE; Ganguli A
    Curr Med Res Opin; 2016; 32(4):721-9. PubMed ID: 26743448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apremilast for the treatment of psoriatic arthritis.
    Souto A; Gómez-Reino JJ
    Expert Rev Clin Immunol; 2015; 11(12):1281-90. PubMed ID: 26503917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small molecule therapy for managing moderate to severe psoriatic arthritis.
    Costa L; Del Puente A; Peluso R; Tasso M; Caso P; Chimenti MS; Sabbatino V; Girolimetto N; Benigno C; Bertolini N; Del Puente A; Perricone R; Scarpa R; Caso F
    Expert Opin Pharmacother; 2017 Oct; 18(15):1557-1567. PubMed ID: 28891341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.